The National Institute for Health and Clinical Excellence (NICE) issued full guidance to the NHS in England, Wales, Scotland and Northern Ireland on Interstitial photodynamic therapy for malignant parotid tumours in May 2008. In accordance with the Interventional Procedures Programme Process Guide, guidance on procedures with special arrangements are reviewed 3 years after publication and the procedure is reassessed if important new evidence is available.

The guidance was considered for reassessment in May 2010 and it was concluded that NICE will not be updating this guidance at this stage. However, if you believe there is new evidence which should warrant a review of our guidance, please contact us via the email address below.


The parotid glands are located in front of the ears and help to produce saliva. A tumour in a parotid gland usually causes a painless swelling on the side of the face where the affected gland is. Only a small number of these tumours are cancerous. In photodynamic therapy (usually abbreviated to PDT), a drug called a 'photosensitising agent' is injected into a vein. A few days later, needles are inserted into the tumour and a special light is shone through them. The light causes the photosensitising agent to destroy the tumour cells.

Coding recommendations


SNOMED CT preferred term (concept ID)

Interstitial photodynamic therapy of malignant tumour of parotid gland (840981000000104)

F45.5 Destruction of lesion of salivary gland

Y13.6 Photodynamic therapy of lesion of organ NOC

Z26.1 Parotid gland

In addition ICD-10 code C07. X Malignant neoplasm of parotid gland or C79.8 Secondary malignant neoplasm of other specified sites is assigned.    

Diagnosis or health condition

SNOMED CT preferred term (concept ID)

Neoplasm of parotid gland (126788000)

Malignant tumor of parotid gland (363379000) 

Your responsibility

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this guidance fully into account. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Commissioners and/or providers have a responsibility to implement the guidance, in their local context, in light of their duties to have due regard to the need to eliminate unlawful discrimination, advance equality of opportunity, and foster good relations. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.